Paul Nathan, MBBS, PhD, FRCP, highlighted the favorable 5-year OS results of tebentafusp for patients with HLA-A*02:01–positive uveal melanoma.
Paul Nathan, MBBS, PhD, MCRP
Advertisement
Articles by Paul Nathan, MBBS, PhD, MCRP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab in MIBC Post-Cystectomy with ctDNA MRD
2
FDA Approves T-DXd in 2 Indications for HER2+ Early Breast Cancer
3
Sac-TMT Significantly Improves PFS/OS in Pretreated Endometrial Cancer
4
Investigators Initiate Dosing in Phase 1b/2 Trial of SNB-101 in ES-SCLC
5